AG环亚官网_环亚AG娱乐_AG环亚集团_新浪新闻
全国免费咨询热线

热门新闻

热门新闻

当前位置:主页 > 热门新闻 >

联系我们

CONTACT

地址:
电话:
传真:
邮箱:

Simcere Pharmaceutical Group to Acquire Additional Stake in

2019-02-06

Simcere to control a 90% stake in Boda

NANJING, China, June 7 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire an 80% stake in Xiangao Investment Company Ltd, an investment company registered in China, as its sole business, holds a 49% stake in Jilin Boda Pharmaceutical Co. Ltd. ("Boda"). After the completion of this acquisition, Simcere will control a 90% stake in Boda.

Boda is a fast-growing manufacturer of injectable stroke management medication. Simcere currently holds a 51% stake in Boda through an acquisition made in September 2007. This additional acquisition further demonstrates Simcere's progress in the field of cardiovascular and cerebrovascular medications.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

For more information, please contact:

Investor and Media Contacts:

Email: ir@simcere.com

In Nanjing:

Frank Zhao

Chief Financial Officer

Simcere Pharmaceutical Group

Tel: +86-25-8556-6666 x8818

In Beijing:

Ruirui Jiang

Brunswick Group

Tel: +86-10-6566-2256

In the United States:

Kate Tellier

Brunswick Group

Tel: +1-212-333-3810

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: +852-3512-5000

本文源自: AG环亚官网

Copyright 2018 AG环亚官网_环亚AG娱乐_AG环亚集团_新浪新闻 版权所有

友情链接: